Antiproliferative effect of trastuzumab combined with carboplatin on Her-2-overexpressing esophageal carcinoma cells
AIM:To investigate the antiproliferative effect of trastuzumab combined with carboplatin on her-2/neu-overexpressing esophageal carcinoma cells.METHODS:The esophageal carcinoma cell lines EC109 and TE3 were cuhured routinely.The expression of her-2/neu of these cell lines was examined by flow cytometry and EC109 cells with her-2/neu-overexpressing were selected to be further studied.The EC109 cells in logarithmic phase were distributed into 3 groups.The first group was treated by trastuzumab alone,the second by carboplatin alone and the third by trastuzumab combined with carboplatin.Each group then was further distributed into 5 subgroups,which were incubated with different doses of above mentioned drugs respectively.MTT assay was performed to observe the inhibitory effects of each dose of each medication,and apoptosis in EC109 cells of each subgroup was measured by Annexin-V/PI assay.RESULTS:The dose-dependent inhibitory effects on EC109 cells with her-2/neuoverexpressing was observed among all 3 groups(P＜0.05),but the group treated by combined drugs exhibited a significantly greater inhibitory effect on cell growth than any single drug when the drug dose was larger than 1 PPC(plasma peak concentration of drug)(P＜0.05).The apoptosis in ECl09 cells of each group was also noted with an observation of significantly higher apoptosis-inducing activity of combined treatment than that of trastuzumab alone or carboplatin alone when the drug dose was larger than 1PPC(P＜0.05).CONCLUSION:The combination of trastuzumab and earboplatin could produce synergistically antiproliferative and apoptosis-inducing effects on her-2/neu-overexpressing esophageal carcinoma EC109 cells.
NETL
NSTL
万方数据
维普
